Get started
Author

Katia Mancuso

Observed names: K Mancuso, K. Mancuso, Mancuso, Katia
ORCID: 0000-0002-1169-0129
Observed ORCID: 0000-0002-1169-0129
OpenAlex ID: A5051226797
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
2015 · Elena Zamagni, Cristina Nanni, et al. · Clinical Cancer Research · 179
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
2015 · E Zamagni, C Nanni, et al. · Leukemia · 144
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
2022 · M. Martello, A. Poletti, et al. · Blood Cancer Journal · 46
PDF
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
2023 · Elena Zamagni, Stefania Oliva, et al. · EClinicalMedicine · 44
PDF
Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
2015 · Beatrice Anna Zannetti, Elena Zamagni, et al. · American Journal of Hematology · 42
PDF
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
2023 · Mattia D’Agostino, Giuseppe Bertuglia, et al. · Blood · 41
PDF
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma
2018 · Serena Rocchi, Paola Tacchetti, et al. · Haematologica · 40
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?
2017 · Giacomo Filonzi, Katia Mancuso, et al. · American Journal of Roentgenology · 40
A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
2020 · Serena Rocchi, Paola Tacchetti, et al. · Hematological Oncology · 35
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
2023 · Niels W C J van de Donk, Monique C Minnema, et al. · The Lancet Oncology · 33
PDF
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation
2015 · A Brioli, G Perrone, et al. · Bone Marrow Transplantation · 28
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
2024 · Marina Martello, Vincenza Solli, et al. · Blood Cancer Journal · 24
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
2023 · Elias K. Mai, Thomas Hielscher, et al. · Leukemia · 24
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study
2023 · Efstathios Kastritis, Evangelos Terpos, et al. · American Journal of Hematology · 22
PDF
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents
2016 · Paola Tacchetti, Annalisa Pezzi, et al. · Haematologica · 22
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens
2016 · Paola Tacchetti, Michele Cavo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
2024 · Paola Tacchetti, Marco Talarico, et al. · Expert Review of Anticancer Therapy · 17
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
2025 · Enrica Antonia Martino, Daniele Derudas, et al. · Hematological Oncology · 16
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
2024 · Paola Tacchetti, Simona Barbato, et al. · Cancers · 16
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
2022 · Enrica Antonia Martino, Concetta Conticello, et al. · Hematological Oncology · 16
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
2013 · Lucia Pantani, Elena Zamagni, et al. · Annals of Hematology · 15
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
2025 · E.A. Martino, S. Palmieri, et al. · ESMO Open · 14
PDF
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
2022 · Ilaria Vigliotta, Silvia Armuzzi, et al. · Frontiers in Oncology · 14
PDF
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review
2024 · Flavia Bigi, Enrica Manzato, et al. · Pharmaceuticals · 13
PDF
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138−CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis
2016 · M Martello, D Remondini, et al. · Leukemia · 13
Works count: 146
Citation count: 1,188
H-index: 17
I10-index: 35
Year
Topic
Type